arrow
M

Michael S. Hofman

Peter MacCallum Cancer Centre
H指数:78
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Oligometastatic prostate cancer in the PSMA PET era: a state-specific narrative review of emerging therapeutic strategies

寡转移性前列腺癌在PSMA PET时代:一种基于特定治疗阶段的叙事性综述新兴治疗策略

2026-10-230
OAAI
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
2025-11-010
PRE
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry

原发性评分(PRIMARY Score)在分期前列腺特异性膜抗原正电子发射断层扫描中的应用与初诊前列腺癌患者总生存期的关系:国际、多中心PROMISE注册研究的结果

2025-10-290
OAAI
Baseline and Early On-treatment Circulating Tumour DNA Fraction Are a Key Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA-617

基线和早期治疗时外周血循环肿瘤DNA比例是接受[177Lu]Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌的关键预后生物标志物

2025-10-290
OAAI
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
A prospective pilot study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer

一项关于在非小细胞肺癌患者放疗期间和放疗后,进行Gallium-68肺通气和灌注PET/CT的前瞻性试点研究

2025-10-100
PRE
Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)

表征碳酸酐酶9和HIF-2α RNA在透明细胞肾细胞癌(ccRCC)中的表达

2025-10-010
OAAI
SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis

SPARC:标准化前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描分析与报告共识:一项德尔菲分析

2025-09-130
PREAI
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值:一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究

2025-07-300
PRE
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE